Novocure-Zai announce MAA approval for Optune to treat GBM patients

Date: 2020-05-15   Author: Saipriya Iyer  Category: #news

Novocure-Zai announce MAA approval for Optune to treat GBM patients

Novocure and Zai Lab Ltd. have recently announced the MAA (Marketing Authorization Application) approval from the China NMPA (National Medical Products Administration). The approval has been given for the use of Optune, in combination with temozolomide, to treat newly diagnosed GBM (glioblastoma) patients. It will also be used as a monotherapy for patients suffering from recurrent GBM. Optune is the 1st treatment for GBM that has been approved in over 15 years in China.

According to Dr. Samantha Du, Zai Lab’s CEO, Chairperson, and Founder, the recent approval is a significant treatment advancement for GBM patients in China and an important milestone for the company. Optune has previously been granted with the Innovative Medical Device Designation. It highlights the importance and differentiation of this novel treatment for patients with GBM. The company appreciates NMPA for this thorough and rapid assessment of the application of Optune, which will help serve high unmet medical needs. Dr. Du further stated that the company is looking forward to working with Novocure, to leverage Tumor Treating Fields and treat several cancer indications, including GBM.

William Doyle, Executive Chairman of Novocure, stated that the company is focusing on the commercialization and development of Tumor Treating Fields to increase the survival rate of several aggressive cancers. He also expressed appreciation towards their partner, Zai Lab, for collectively working to obtain Optune approval in Greater China.

Tumor Treating Fields therapy is delivered by Optune to the tumor region. It has been used to treat over 15,000 GBM patients to date, globally. The therapy has been approved by the FDA for the treatment of MPM (malignant pleural mesothelioma), which is expected to be the next Marketing Authorization Application filed with the China NMPA. It is also under Phase 3 pivotal trials to treat ovarian cancer, pancreatic cancer, non-small cell lung cancer, and brain metastases, and in Phase 2 pilot trials to treat gastric cancer and liver cancer. In China, over 1.5 million patients are diagnosed with gastric, ovarian, non-small cell lung, and pancreatic cancers, collectively in a year.

Source credit:https://www.businesswire.com/news/home/20200513005458/en/China-NMPA-Approves-Optune%C2%AE-Treatment-Newly-Diagnosed



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

India-based Kaizen AI set to influence the $1.36 trillion GCC realty sector

Author: Pankaj Singh

Kaizen AI, a prominent technology firm that uses AI to revolutionize large-scale building projects, is entering the lucrative GCC real estate sector, where the value of planned and under-construction projects is projec...


Microsoft expands partnership with Oracle to Deliver Oracle Database Services

Author: Pankaj Singh

Microsoft Corp. and Oracle Corp. have reportedly announced the availability of Oracle Database@Azure, which provides direct access to the Oracle database services operating on Oracle Cloud Infrastructure ...


Reliance Industries and NVIDIA join hands to advance AI in India

Author: Pankaj Singh

Indian billionaire Mukesh Ambani-owned Reliance Industries Ltd. has reportedly announced a partnership with U.S.-based chipmaker NVIDIA for advancing AI in India.

Apparently, Indi...